Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Dr. Bob Cobuzzi
PharmaShots Interview: Diffusion’s Dr. Bob Cobuzzi Shares Insights on the Trans Sodium Crocetinate (TSC) to Improve Hypoxia
In an interview with PharmaShots, Dr. Bob Cobuzzi, CEO, President, and Board Member at Diffusion shared his views on the trans sodium crocetinate (TSC) to improve patient outcomes & paradigm of oxygen deprivation treatment Shots: Diffusion's TSC directly targets and relieves oxygen-deprivation in affected tissue by enhancing oxygen diffusion & was designed to treat hypoxia include trauma, heart attack, stroke,…
November 3, 2021
Viewpoints_Brady Granier
PharmaShots Interview: BioCorRx’ Brady Granier Shares Insights on the New Agreement with Recro to Support BICX104
In an interview with PharmaShots, Brady Granier, CEO, President, and Director at BioCorRx shared his views on the companies existing collaboration & expands with the signing of a new development and manufacturing agreement to support BICX104 for opioid use disorder Shots: The companies have expanded an ongoing collaboration by signing a new development and manufacturing agreement to support BICX104 for…
November 2, 2021
Viewpoints_Txema Sanz
PharmaShots Interview: Astellas’ Txema Sanz Shares Insights on the Evrenzo (roxadustat) for Symptomatic Anemia Associated with Chronic Kidney Disease
In an interview with PharmaShots, Txema Sanz, Senior Vice President and Head of the Global Medical Specialties at Astellas shared his views on the EC's approval of Evrenzo (roxadustat) for the Treatment of symptomatic anemia associated with Chronic Kidney Disease Shots: The approval is based on the P-III program including 8 studies evaluating Evrenzo in 9600 patients with symptomatic anemia associated with…
October 27, 2021
Viewpoints_Rich Birhanzel
PharmaShots Interview: Accenture’s Rich Birhanzel Shares Insight on the Investment in ixlayer
In an interview with PharmaShots, Rich Birhanzel, Senior Managing Director & Global Health Lead at Accenture shared his views on the investment in ixlayer to provide health solutions for diagnostic testing Shots: The company has made a strategic investment in ixlayer through Accenture Ventures to expand access to virtual diagnostic health testing. The company's telehealth platform allows players across the healthcare ecosystem…
October 22, 2021
Viewpoints_Anish Suri
PharmaShots Interview: Cue Biopharma’s Anish Suri Shares Insights on the Data of CUE-401 Presented at 2021 FOCIS Annual Meeting
In an interview with PharmaShots, Anish Suri, Ph.D., President, and Chief Scientific Officer at Cue Biopharma shared his views on new preclinical data of CUE-401 for the treatment of autoimmune diseases at the 2021 FOCIS Annual Meeting Shots: The company has reported the preclinical data of CUE-401 which can induce & expand regulatory T cells in vitro and in vivo & has the potential to…
October 15, 2021
Viewpoints_Brandon Smith
PharmaShots Interview: Prothena’s Brandon Smith Shares Insight on the Acquisition of Prothena and Novo Nordisk
In an interview with PharmaShots, Brandon Smith, Chief Business Officer at Prothena shared his views on Novo Nordisk's acquisition of Prothena's ATTR amyloidosis program includes PRX004 Shots: The companies have entered into a definitive purchase agreement in which Novo Nordisk has acquired Prothena's PRX004 and broader ATTR amyloidosis program Novo Nordisk acquires Prothena's subsidiary and gets WW rights to the IP and…
October 15, 2021
Viewpoints_Dr. Pierre Pellier
PharmaShots Interview: CTMA-Dr. Pierre Pellier Shares Insight on CT-SCOUT to Detect Patients for Clinical Trials in IBD
In an interview with PharmaShots, Dr. Pierre Pellier, CEO of CTMA, share his views on CT-SCOUT that helps to boost patient recruitment in the clinical trials for IBD Shots: CTMA developed the web mobile platform, CT-Scout to boost patient recruitment in the clinical trials by facilitating a quick and simple study detection for eligible patients CT-Scout is currently available in…
October 11, 2021
Viewpoints_Dr. Barbara Klencke
PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra’s Agreement with AstraZeneca for AZD5153
In an interview with PharmaShots, Dr. Barbara Klencke, MD, Chief Medical Officer at Sierra Oncology share her views on the license agreement for AZD5153 with AstraZeneca to treat myelofibrosis Shots: AstraZeneca signs an exclusive license agreement with Sierra for AZD5153 to expand myelofibrosis pipeline. The agreement will provide a novel compound into Sierra's pipeline to supply therapies for rare cancers Sierra plans…
October 11, 2021
Viewpoints_Salom Juethner
PharmaShots Interview: Takeda Salom Juethner Shares Insights on the Data Publication to Support the Sustained Safety and Efficacy of Takhzyro
In an interview with PharmaShots, Salomé Juethner, Senior Medical Director, Rare Diseases at Takeda shared her views on the P-III HELP study of Takhzyro for the prevention of hereditary angioedema attacks in the Journal Allergy Shots: The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged =12yrs. with HAE attacks for ~2.5yrs.…
October 6, 2021
Load more